SCHEMBL17100709

SCHEMBL17100709

COc1ccc(S(=O)(=O)N2CCC3(CC2)CN(C(=O)OC(C)(C)C)C3)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.60
MEN1 O00255 2/20 0.60
KMT2A Q03164 2/20 0.60
MMP1 P03956 2/20 0.53
MMP9 P14780 2/20 0.53
PKM P14618 2/20 0.53
NPC1 O15118 1/20 0.53
PKLR P30613 1/20 0.53
RAB9A P51151 1/20 0.53
MMP3 P08254 1/20 0.53
MMP7 P09237 1/20 0.53
ALDH1A1 P00352 4/20 0.53
USP2 O75604 2/20 0.53
CYP2D6 P10635 2/20 0.53
CYP2C9 P11712 1/20 0.53
HIF1A Q16665 1/20 0.53
CYP1A2 P05177 1/20 0.53
STS P08842 1/20 0.52
MMP13 P45452 1/20 0.52
HTT P42858 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17102066 0.92 STS (0.55) CYP3A4MEN1KMT2AMMP1MMP9
SCHEMBL26064727 0.87 TGM2 (0.47) CYP3A4MEN1KMT2AALDH1A1LMNA
SCHEMBL18153290 0.86 PKM (0.66) MMP1MMP9PKMNPC1PKLR
SCHEMBL17101977 0.84 CYP3A4 (0.65) CYP3A4MEN1KMT2APKMNPC1
SCHEMBL17102104 0.84 PKM (0.71) CYP3A4MEN1KMT2APKMNPC1
SCHEMBL17102096 0.81 CYP3A4 (0.62) CYP3A4MEN1KMT2APKMNPC1
SCHEMBL17101969 0.81 CYP3A4 (0.64) CYP3A4MEN1KMT2APKMNPC1
SCHEMBL17101980 0.79 ALDH1A1 (0.58) CYP3A4MEN1KMT2APKMNPC1
SCHEMBL17102082 0.79 CYP3A4 (0.59) CYP3A4MEN1KMT2APKMNPC1
SCHEMBL17102110 0.78 CYP3A4 (0.56) CYP3A4MEN1KMT2APKMNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200140400-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2020-05-07 US disclosed
US-10562869-B2 Oxadiazole compounds REMYND NV (BE) 2020-02-18 US disclosed
EP-3119782-B1 2,7-DIAZASPIRO[3.5]NONANE COMPOUNDS REMYND NV (BE) 2018-01-31 EP disclosed
US-9750745-B2 2,7-diazaspiro[3.5]nonane compounds REMYND NV (BE) 2017-09-05 US disclosed
US-20170157137-A1 2,7-DIAZASPIRO[3.5]NONANE COMPOUNDS REMYND NV (BE) 2017-06-08 US disclosed
US-9617264-B2 2,7-diazaspiro[3.5]nonane compounds REMYND NV (BE) 2017-04-11 US disclosed
US-20170073319-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2017-03-16 US disclosed
EP-3119774-A1 OXADIAZOLE COMPOUNDS reMynd NV (BE) 2017-01-25 EP disclosed
EP-3119782-A1 2,7-DIAZASPIRO[3.5]NONANE COMPOUNDS reMynd NV (BE) 2017-01-25 EP disclosed
US-20170015665-A1 2,7-DIAZASPIRO[3.5]NONANE COMPOUNDS REMYND NV (BE) 2017-01-19 US disclosed
WO-2015140130-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2015-09-24 WO disclosed
WO-2015140132-A1 2,7-DIAZASPIRO[3.5]NONANE COMPOUNDS REMYND NV (BE) 2015-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170157137-A1 2,7-DIAZASPIRO[3.5]NONANE COMPOUNDS PSEN1, MAPT, PSEN2 CYP3A4 1773/4885MEN1 1633/4885KMT2A 4531/4885
US-10562869-B2 Oxadiazole compounds OXA1L, PSEN1, MAPT CYP3A4 738/4885MEN1 2665/4885KMT2A 4820/4885
US-20170015665-A1 2,7-DIAZASPIRO[3.5]NONANE COMPOUNDS PSEN1, MAPT, PSEN2 CYP3A4 1773/4885MEN1 1633/4885KMT2A 4531/4885
US-20200140400-A1 OXADIAZOLE COMPOUNDS OXA1L, PSEN1, MAPT CYP3A4 847/4885MEN1 2837/4885KMT2A 4819/4885
US-20170073319-A1 OXADIAZOLE COMPOUNDS OXA1L, PSEN1, MAPT CYP3A4 738/4885MEN1 2665/4885KMT2A 4820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.